Pidilizumab (CT-011) is the first PD-1-targeting humanized mAb to be tested in clinical trials for melanoma, NSCLC, renal cell carcinoma, head and neck cancers, lymphoma and several other cancers 70. Here, PDCD1 is linked to non-small cell lung carcinoma.